
New chair for British Generic Manufacturers Association
pharmafile | January 20, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | bgma, thomas broeer
Thomas Broeer has been elected as chair of The British Generic Manufacturers Association (BGMA).
Broeer, managing director of Kent Pharmaceuticals, will maintain the role for the next two years and replaces Kim Innes, a director with Teva, who will continue for a further year as vice-chair of the association.
Broeer takes with him more than 20 years of international pharmaceutical business management experience to the role, from working both within the generic and branded industries.
Prior to taking up the role with Kent Pharmaceuticals earlier this year, Broeer had previously held senior management roles with Mylan in the UK and Germany.
He said: “I am delighted to be taking on the role of chair of the BGMA. Generics play a vital role in the UK in ensuring access to medicines. The competitive, multi-source market delivers huge savings to the NHS every year providing a secure supply of cost effective medicines for patients. ”
Related Content

Insider Interview: BGMA Director Warwick Smith disputes recent generic price increase claims
Warwick Smith, Director of the British Generic Manufacturer’s Association (BGMA), discusses the recent data suggesting …

British Biosimilars Association launches in UK
A new industry body, the British Biosimilars Association, has been formally launched today with the …

OPINION: ‘More work remains if biosimilars are to fulfil their potential’
Despite having a mature generics market which fulfils more than three-quarters of all prescriptions in …






